BioSpace News Archive

Intellia Therapeutics, Inc. (NASDAQ:NTLA), today announced that it has entered into a lease agreement to develop a 140,000-square-foot manufacturing facility in Waltham, Massachusetts, to support the manufacturing of key components for its CRISPR-based investigational therapies.

Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers, today announced that it has completed patient enrollment in Part A of the Phase 2/3 RINGSIDE clinical trial evaluating AL102 in desmoid tumors.

InnerScope Hearing Technologies Inc. announced the introduction of its own new internal customer call center for its subsidiary HearingAssist of nearly 500,000 customers and its iHear branded hearing aid customers.

Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced the appointment of Lisa Beck as Chief Business Officer.

Poseida Therapeutics, Inc. (NASDAQ: PSTX), today announced that the Company plans to highlight its clinical and preclinical pipeline progress during a virtual R&D Day to be held today beginning at 10:00am ET / 7:00am PT.

Saranas, a company focused on improving patient outcomes through early detection and monitoring of internal bleeding complications, announced today that the U.S. Department of Commerce’s United States Patent and Trademark Office (USPTO) has issued them Patent No. 11,224,414.

Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today announced that it has obtained approval from the Monash Health Human Research Ethics Committee (HREC) to initiate a Phase 1/2, first-in-human trial of AU-007, a monoclonal antibody computationally designed by Biolojic Design.

Agilent Technologies Inc. (NYSE: A) announced today that researchers from the QIMR Berghofer Medical Research Institute in Brisbane, Australia, collaborated with Agilent experts on a proof-of-concept FTIR-based saliva COVID-19 testing workflow using the Agilent Cary 630 FTIR Spectrometer.

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended December 31, 2021, and provided an update on the Company’s clinical development programs and regulatory and commercial outlook.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the first patient has been enrolled in a Phase 3 clinical trial (OPTIC-J) in Japan evaluating teprotumumab for the treatment of active TED.